We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Last month, the FDA threatened to take regulatory action against the devicemakers after analyses found that the contamination rates have increased. Read More
The test identified residual disease in non-small cell lung, bladder, breast and colorectal cancer patients up to two years earlier than standard imaging. Read More